Hemogenyx, Nitto Begin Feasibility Study on In Vivo CAR-T
The study will evaluate targeted LNP delivery of Hemogenyx’s FLT3-CAR mRNA to T cells, exploring an off-the-shelf in vivo CAR-T approach alongside its ongoing HG-CT-1 autologous program.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.